News and Trends 26 Mar 2018 New Antibiotic for Urinary Tract Infections Gets Positive Phase II Results Allecra Therapeutics has obtained positive Phase II study results for its new urinary tract infection antibiotic, supporting the launch of a Phase III trial. Allecra Therapeutics, a French-German biotech, has obtained positive Phase II trial results for its lead antibiotic candidate for treating urinary tract infections. The drug, AAU101, was given to patients intravenously with cefepemine, another antibiotic […] March 26, 2018 - 1 minutemin - By Alexander Burik Share WhatsApp Twitter Linkedin Email
More News! 1 Mar 2018 Just a Single Dose of this Drug Boosts the Survival of Heart Failure Patients Berlin Cures’ drug fights off self-reactive antibodies that are associated with 80% of heart failure cases to improve heart function and patient survival. Berlin Cures was founded in 2014 to make use of research being carried out at Charité Medical University and the Max-Delbrueck-Center in Berlin. The biotech has achieved promising clinical data that suggests its first […] March 1, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 23 Feb 2018 Crack Open the Champagne, AiCuris’ Antiviral Launched in Germany Update (23/02/2018): Merck Sharp & Dohme (MSD), licensee of AiCuris, has launched letermovir in Germany under the trade name Prevymis. The antiviral drug will be available to patients undergoing a hematopoietic stem cell transplant (HSCT) to prevent reactivation of latent human cytomegalovirus (CMV), which can prove lethal in the weakened state of this patients. Update (31/01/2018): […] February 23, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
Interview 22 Feb 2018 Could a New Approach Help Us to Overcome Resistance to HIV Treatment? Clara chatted with Christian Setz, CEO of Immunologik, to find out how the company is developing a new HIV treatment that could overcome resistance to anti-retroviral drugs. Over 36 million people are living with human immunodeficiency virus (HIV), which has led to many biotechs, including Abivax, working on better options for patients. Immunologik, a recent ‘Biotech of the Week’, is […] February 22, 2018 - 4 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 12 Feb 2018 No Nonsense Boehringer Ingelheim Jettisons Failing Alzheimer’s Disease Drug Boehringer Ingelheim has ditched its Alzheimer’s drug after it failed to meet the endpoints of a Phase II trial but will continue to look at it for the treatment of schizophrenia. One of Germany’s biggest pharma companies, Boehringer Ingelheim, has given up on the development of its Alzheimer’s drug, BI 409306, which underwent Phase II testing. The […] February 12, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
Interview 12 Feb 2018 MorphoSys’ CEO Tells Us What’s Next for Europe’s Antibody Expert After 25 years, MorphoSys finally got over the line in 2017 with the FDA approval of its first antibody. CEO Simon Moroney tells us how the company hopes to build on its recent success. It may have started out as a tech provider, but MorphoSys now stands as one of the leading German biotechs, specializing […] February 12, 2018 - 8 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 29 Jan 2018 London Tops Europe for Life Sciences Investment in 2017 Investment in London’s life sciences companies reached almost £1B in 2017, beating the likes of Berlin and Paris to top spot. A new study has found that London’s life sciences industry received the most investment out of any city in Europe in 2017. Over the last 5 years, companies in the capital have raised £2.8Bn (€3.2Bn), with £909M […] January 29, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 29 Jan 2018 Mapping of the Axolotl’s Genome Boosts the Regenerative Medicine Field Salamanders have long been a useful model for regenerative medicine due to their ability to regrow entire limbs. Now, scientists have found the genes that drive the process. Scientists in Vienna, Dresden, and Heidelberg are the first to completely map the genome of the axolotl salamander. Despite its popularity as a biological model and use for […] January 29, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
Interview 29 Jan 2018 Meet the CEO of the Other Big Biotech Acquisition Target in 2017 Christian Schetter’s company, Rigontec, was acquired by MSD last year for nearly half a billion euro. How did he and the company do it, with only one early-stage candidate? There were exactly two notable biotech acquisitions in Europe last year: Actelion and a smaller startup based in Munich called Rigontec, which had an RNA candidate […] January 29, 2018 - 9 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 17 Jan 2018 Here’s Your New Year’s Resolution: Get Your Immune System in Shape If you’re having trouble deciding on a New Year’s resolution, why not train up your immune system? Scientists believe this could help prevent the side effects of chemotherapy. Researchers at Technische Universitaet Dresden believe that by ‘training’ the immune system, cancer patients undergoing chemotherapy could be spared some of the trauma. The study, published in Cell, […] January 17, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 15 Jan 2018 This is Why You Should Avoid Eating too Much Junk Food Following last week’s article about the importance of eating plenty of fruit and vegetables, German researchers have unearthed another link between junk food and diabetes and heart disease. Researchers from the University of Bonn, Germany, have found that an unhealthy diet can cause the immune system to act as if it is responding to bacterial […] January 15, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 11 Jan 2018 German Biotech Gets FDA Approval to Start an Ulcerative Colitis Phase II Study The FDA will allow Immunic Therapeutics to commence a Phase II clinical trial to test its oral investigational drug, IMU-838, for the treatment of ulcerative colitis. Immunic Therapeutics, which closed a €31M Series A last September, specializes in the development of drugs for the treatment of chronic inflammatory diseases. At the moment, the company has two ongoing […] January 11, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email